 |
 |
 |
 |
 |
|
 |
 |
 |
Our Company Literature
Search our company literatureBCS
This non-GLP assay is used to determine a preliminary BCS solubility classification by measuring the quasi-equilibrium solubility of a test compound in aqueous USP buffer systems at two pH values between 1.0 and 7.4.
Click Here to Download
This GLP assay is used to determine a BCS solubility classification by measuring the quasi-equilibrium solubility of a test compound in aqueous USP buffer systems at four pH values between 1.0 and 7.4.
Click Here to Download
This non-GLP assay is used to determine a preliminary BCS permeability classification by measuring the permeability of a test compound through Caco-2 cell monolayers in both the apical-to-basolateral and basolateral-to-apical direction.
Click Here to Download
This GLP assay is used to determine the BCS permeability classification of a test compound across Caco-2 cell monolayers at three concentrations and two pH values.
Click Here to Download
Formulation
This screening assay is used to determine the bioavailability of test compounds relative to a reference compound after oral administration to rats.
Click Here to Download
This assay is used to determine the absolute bioavailability of a test compound in mice.
Click Here to Download
This assay is used to determine the bioavailability of a test compound in dogs when the compound is administered by at least two different routes.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay is used to determine the bioavailability / exposure of a test compound in dogs after two routes of administration (non-crossover).
Click Here to Download
Medical Devices
This assay is used to determine the acute systemic toxicity of a device or device material in mice or rabbits and is required for most medical-grade materials and devices that are intended to make contact with the patient for more than 24 hours.
Click Here to Download
Physicochemical
This assay is used to determine the quasi-equilibrium solubility of a test compound at a specified temperature and pH in a specified matrix using the shake-flask method.
Click Here to Download
This assay is used to determine the LogD of a test compound at a specified pH using the shake-flask method.
Click Here to Download
In this assay a Sirius GLpKa system is used to determine the pKa, LogP, and LogD values of a test compound.
Click Here to Download
This assay is used to determine the solubility of a test compound at room temperature in phosphate buffer at pH 7.4.
Click Here to Download
This assay is used to determine the LogD of a test compound at pH 7.4 using the shake-flask method.
Click Here to Download
This assay is used to determine the chemical stability of a test compound in simulated or natural gastrointestinal fluids.
Click Here to Download
This assay is used to determine the stability of test compound in blood plasma for various species, including humans.
Click Here to Download
This assay is used to determine the stability of a test compound in whole blood or plasma from mouse, rat, rabbit, dog, monkey, or human.
Click Here to Download
This assay is used to determine the chemical stability of a test compound in buffer.
Click Here to Download
This non-GLP assay is used to determine a preliminary BCS solubility classification by measuring the quasi-equilibrium solubility of a test compound in aqueous USP buffer systems at two pH values between 1.0 and 7.4.
Click Here to Download
This GLP assay is used to determine a BCS solubility classification by measuring the quasi-equilibrium solubility of a test compound in aqueous USP buffer systems at four pH values between 1.0 and 7.4.
Click Here to Download
This assay is used to develop dose vehicle(s) for a test compound, as a solution or suspension prior to in vivo pharmacokinetic testing.
Click Here to Download
Preclinical PK
This screening assay is used to determine the bioavailability of test compounds relative to a reference compound after oral administration to rats.
Click Here to Download
Determination of brain-to-plasma ratio of a test compound in rats or mice following IV or oral dosing.
Click Here to Download
This assay uses in situ brain perfusion to determine both the potential brain penetration of test compound and whether it is a P-gp substrate.
Click Here to Download
This assay is used to determine the absolute bioavailability of a test compound in mice.
Click Here to Download
This assay is used to determine the bioavailability of a test compound in dogs when the compound is administered by at least two different routes.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male mice.
Click Here to Download
This screening assay is used to determine the bioavailability / exposure of test compounds after two routes of administration to male rats.
Click Here to Download
This assay is used to determine the bioavailability / exposure of test compounds in male dogs after two routes of administration.
Click Here to Download
This assay uses in vivo carotid infusion to determine the extent of brain penetration of test compound in a physiological setting, including plasma protein binding.
Click Here to Download
Transporters
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in the apical-to-basolateral and basolateral- to-apical direction.
Click Here to Download
This assay is used to determine the P-gp interaction with a test compound using MDR1-MDCK cell monolayers in both the presence and absence of a P-gp inhibitor.
Click Here to Download
This assay is used to determine the bidirectional permeability of a test compound through intestinal tissue segments (duodenum, ileum, jejunum and colon).
Click Here to Download
This assay is used to determine the permeability of a test compound through Caco-2 cell monolayers in both the apical-to-basolateral and basolateral-to-apical direction.
Click Here to Download
This assay is used to determine if a test compound is a human P-gp substrate by measuring its bidirectional permeability across MDR1-MDCK and MDCK cell monolayers in the presence and absence of P-gp inhibitors.
Click Here to Download
This assay is used to determine if a test compound is a P-gp inhibitor by measuring its effect on the bidirectional permeability of the P-gp substrate, digoxin, through MDR1-MDCK or Caco-2 cell monolayers.
Click Here to Download
This assay is used to determine the P-gp interaction with a test compound using CellPort™ CPT-B1 BCRP-knockdown cell monolayers in both the presence and the absence of a P-gp inhibitor.
Click Here to Download
This assay is used to determine the BCRP interaction with a test compound using CellPort™ CPT-B1 BCRP-knockdown cell monolayers and wild-type Caco-2 cell monolayers.
Click Here to Download